Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Semaglutide has surged in popularity over the past two years, thanks to its remarkable effectiveness as a long-acting GLP-1 ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

SAP gains on cloud strength, NVO faces obesity setbacks, and TMO leans on AI and innovation amid macro headwinds.

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Once-weekly semaglutide improved glycemia and reduced weight in adults with type 1 diabetes and obesity without increasing hypoglycemia.

A new study suggests semaglutide may lower dementia risk in type 2 diabetes patients, particularly among women and older adults. More research needed.

There is an expectation that Novo Nordisk will file a regulatory application for semaglutide in MASH within a year. It is also believed that insurance coverage for GLP-1s will gradually improve.